Sartorius Buys Second Service Provider
Cellca provides services and media, and licenses to its proprietary technology. Its technology includes an expression system, host cell line, media system and scale-up process. Earlier this year, Sartorius acquired BioOutsource, another service provider focused on biosimilar production (see IBO 4/30/15).
Aubagne, France and Goettingen, Germany 7/2/15—Sartorius Stedim Biotech (SSB) has acquired Cellca for an undisclosed amount. Cellca provides process-development services for biopharmaceutical and biosimilar companies. Based in Germany with around 30 employees, Cellca posted 2014 revenues of €6 million ($8 million = €0.75 = $1). “Together with our single-use products, media and testing services, we are creating an attractive package, above all for young biopharmaceutical companies that need robust processes for the manufacture of their biologics,” stated Reinhard Vogt, member of the SSB Executive Committee for Marketing and Sales.
